flow trial semaglutide kidney outcomes nejm 2024 hazard ratio FLOW: Kidney outcome results for GLP-1RA FLOW trial Ozempic® (semaglutide injection)

Metabolic cues from the microenvironment act as a major selective factor for cancer progression and metastases formation

Discuss alternative weight-management strategies with your provider

However, there is evidence to suggest that the injections may affect the effectiveness of oral contraceptives [14], and they are not suitable to be taken while pregnant or breastfeeding

Conversely, if you have genetic patterns favoring GLP-1 pathway activation, semaglutide often provides excellent weight loss with fewer GI side effects

The receiver operating characteristic (ROC) curve analysis was used to determine the area under the curve (AUC) and cut-off values of serum LC and ALC